193 related articles for article (PubMed ID: 34171447)
21. Smoothened loss is a characteristic of neuroendocrine prostate cancer.
Wang L; Li H; Li Z; Li M; Tang Q; Wu C; Lu Z
Prostate; 2021 Jun; 81(9):508-520. PubMed ID: 33955576
[TBL] [Abstract][Full Text] [Related]
22. Adrenomedullin, an autocrine/paracrine factor induced by androgen withdrawal, stimulates 'neuroendocrine phenotype' in LNCaP prostate tumor cells.
Berenguer C; Boudouresque F; Dussert C; Daniel L; Muracciole X; Grino M; Rossi D; Mabrouk K; Figarella-Branger D; Martin PM; Ouafik L
Oncogene; 2008 Jan; 27(4):506-18. PubMed ID: 17637748
[TBL] [Abstract][Full Text] [Related]
23. Notch signaling modulates hypoxia-induced neuroendocrine differentiation of human prostate cancer cells.
Danza G; Di Serio C; Rosati F; Lonetto G; Sturli N; Kacer D; Pennella A; Ventimiglia G; Barucci R; Piscazzi A; Prudovsky I; Landriscina M; Marchionni N; Tarantini F
Mol Cancer Res; 2012 Feb; 10(2):230-8. PubMed ID: 22172337
[TBL] [Abstract][Full Text] [Related]
24. Interleukin-6 regulates androgen receptor activity and prostate cancer cell growth.
Culig Z; Bartsch G; Hobisch A
Mol Cell Endocrinol; 2002 Nov; 197(1-2):231-8. PubMed ID: 12431817
[TBL] [Abstract][Full Text] [Related]
25. GRK3 is a direct target of CREB activation and regulates neuroendocrine differentiation of prostate cancer cells.
Sang M; Hulsurkar M; Zhang X; Song H; Zheng D; Zhang Y; Li M; Xu J; Zhang S; Ittmann M; Li W
Oncotarget; 2016 Jul; 7(29):45171-45185. PubMed ID: 27191986
[TBL] [Abstract][Full Text] [Related]
26. Icaritin suppresses development of neuroendocrine differentiation of prostate cancer through inhibition of IL-6/STAT3 and Aurora kinase A pathways in TRAMP mice.
Sun F; Zhang ZW; Tan EM; Lim ZLR; Li Y; Wang XC; Chua SE; Li J; Cheung E; Yong EL
Carcinogenesis; 2016 Jul; 37(7):701-711. PubMed ID: 27207661
[TBL] [Abstract][Full Text] [Related]
27. Snail transcription factor regulates neuroendocrine differentiation in LNCaP prostate cancer cells.
McKeithen D; Graham T; Chung LW; Odero-Marah V
Prostate; 2010 Jun; 70(9):982-92. PubMed ID: 20166136
[TBL] [Abstract][Full Text] [Related]
28. Multipathways for transdifferentiation of human prostate cancer cells into neuroendocrine-like phenotype.
Zelivianski S; Verni M; Moore C; Kondrikov D; Taylor R; Lin MF
Biochim Biophys Acta; 2001 May; 1539(1-2):28-43. PubMed ID: 11389966
[TBL] [Abstract][Full Text] [Related]
29. Interleukin-6 inhibits the growth of prostate cancer xenografts in mice by the process of neuroendocrine differentiation.
Wang Q; Horiatis D; Pinski J
Int J Cancer; 2004 Sep; 111(4):508-13. PubMed ID: 15239127
[TBL] [Abstract][Full Text] [Related]
30. Involvement of cholesterol-rich lipid rafts in interleukin-6-induced neuroendocrine differentiation of LNCaP prostate cancer cells.
Kim J; Adam RM; Solomon KR; Freeman MR
Endocrinology; 2004 Feb; 145(2):613-9. PubMed ID: 14563701
[TBL] [Abstract][Full Text] [Related]
31. Androgen-responsive and -unresponsive prostate cancer cell lines respond differently to stimuli inducing neuroendocrine differentiation.
Marchiani S; Tamburrino L; Nesi G; Paglierani M; Gelmini S; Orlando C; Maggi M; Forti G; Baldi E
Int J Androl; 2010 Dec; 33(6):784-93. PubMed ID: 20088946
[TBL] [Abstract][Full Text] [Related]
32. Isoform 1 of TPD52 (PC-1) promotes neuroendocrine transdifferentiation in prostate cancer cells.
Moritz T; Venz S; Junker H; Kreuz S; Walther R; Zimmermann U
Tumour Biol; 2016 Aug; 37(8):10435-46. PubMed ID: 26846108
[TBL] [Abstract][Full Text] [Related]
33. A cross-talk between the androgen receptor and the epidermal growth factor receptor leads to p38MAPK-dependent activation of mTOR and cyclinD1 expression in prostate and lung cancer cells.
Recchia AG; Musti AM; Lanzino M; Panno ML; Turano E; Zumpano R; Belfiore A; Andò S; Maggiolini M
Int J Biochem Cell Biol; 2009 Mar; 41(3):603-14. PubMed ID: 18692155
[TBL] [Abstract][Full Text] [Related]
34. Hyperactive mTOR induces neuroendocrine differentiation in prostate cancer cell with concurrent up-regulation of IRF1.
Kanayama M; Hayano T; Koebis M; Maeda T; Tabe Y; Horie S; Aiba A
Prostate; 2017 Nov; 77(15):1489-1498. PubMed ID: 28905415
[TBL] [Abstract][Full Text] [Related]
35. [Infiltrating mast cells promote neuroendocrine differentiation and increase docetaxel resistance of prostate cancer cells by up-regulating p21].
Ou YH; Jiang YD; Li Q; Zhuang YJ; Dang Q; Tan WL
Nan Fang Yi Ke Da Xue Xue Bao; 2018 Jun; 38(6):723-730. PubMed ID: 29997096
[TBL] [Abstract][Full Text] [Related]
36. Up-Regulated Expression of LAMP2 and Autophagy Activity during Neuroendocrine Differentiation of Prostate Cancer LNCaP Cells.
Morell C; Bort A; Vara-Ciruelos D; Ramos-Torres Á; Altamirano-Dimas M; Díaz-Laviada I; Rodríguez-Henche N
PLoS One; 2016; 11(9):e0162977. PubMed ID: 27627761
[TBL] [Abstract][Full Text] [Related]
37. Secretogranin II is overexpressed in advanced prostate cancer and promotes the neuroendocrine differentiation of prostate cancer cells.
Courel M; El Yamani FZ; Alexandre D; El Fatemi H; Delestre C; Montero-Hadjadje M; Tazi F; Amarti A; Magoul R; Chartrel N; Anouar Y
Eur J Cancer; 2014 Nov; 50(17):3039-49. PubMed ID: 25307750
[TBL] [Abstract][Full Text] [Related]
38. Interleukin-6: a bone marrow stromal cell paracrine signal that induces neuroendocrine differentiation and modulates autophagy in bone metastatic PCa cells.
Delk NA; Farach-Carson MC
Autophagy; 2012 Apr; 8(4):650-63. PubMed ID: 22441019
[TBL] [Abstract][Full Text] [Related]
39. Stimulation of neuroendocrine differentiation in prostate cancer cells by GHRH and its blockade by GHRH antagonists.
Muñoz-Moreno L; Carmena MJ; Schally AV; Prieto JC; Bajo AM
Invest New Drugs; 2020 Jun; 38(3):746-754. PubMed ID: 31312936
[TBL] [Abstract][Full Text] [Related]
40. p38MAPK activation is involved in androgen-independent proliferation of human prostate cancer cells by regulating IL-6 secretion.
Shida Y; Igawa T; Hakariya T; Sakai H; Kanetake H
Biochem Biophys Res Commun; 2007 Feb; 353(3):744-9. PubMed ID: 17196171
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
